scholarly journals At a Glance: An Update on Neuroimaging and Retinal Imaging in Alzheimer’s Disease and Related Research

Author(s):  
J. Ford ◽  
D. Kafetsouli ◽  
H. Wilson ◽  
C. Udeh-Momoh ◽  
M. Politis ◽  
...  

Neuroimaging serves a variety of purposes in Alzheimer’s disease (AD) and related dementias (ADRD) research - from measuring microscale neural activity at the subcellular level, to broad topological patterns seen across macroscale-brain networks, and everything in between. In vivo imaging provides insight into the brain’s structure, function, and molecular architecture across numerous scales of resolution; allowing examination of the morphological, functional, and pathological changes that occurs in patients across different AD stages (1). AD is a complex and potentially heterogenous disease, with no proven cure and no single risk factor to isolate and measure, whilst known risk factors do not fully account for the risk of developing this disease (2). Since the 1990’s, technological advancements in neuroimaging have allowed us to visualise the wide organisational structure of the brain (3) and later developments led to capturing information of brain ‘functionality’, as well as the visualisation and measurement of the aggregation and accumulation of AD-related pathology. Thus, in vivo brain imaging has and will continue to be an instrumental tool in clinical research, mainly in the pre-clinical disease stages, aimed at elucidating the biological complex processes and interactions underpinning the onset and progression of cognitive decline and dementia. The growing societal burden of AD/ADRD means that there has never been a greater need, nor a better time, to use such powerful and sensitive tools to aid our understanding of this undoubtedly complex disease. It is by consolidating and reflecting on these imaging advancements and developing long-term strategies across different disciplines, that we can move closer to our goal of dementia prevention. This short commentary will outline recent developments in neuroimaging in the field of AD and dementia by first describing the historical context of AD classification and the introduction of AD imaging biomarkers, followed by some examples of significant recent developments in neuroimaging methods and technologies.

2018 ◽  
Vol 19 (12) ◽  
pp. 3702 ◽  
Author(s):  
Grazia Femminella ◽  
Tony Thayanandan ◽  
Valeria Calsolaro ◽  
Klara Komici ◽  
Giuseppe Rengo ◽  
...  

Alzheimer’s disease is the most common form of dementia and is a significant burden for affected patients, carers, and health systems. Great advances have been made in understanding its pathophysiology, to a point that we are moving from a purely clinical diagnosis to a biological one based on the use of biomarkers. Among those, imaging biomarkers are invaluable in Alzheimer’s, as they provide an in vivo window to the pathological processes occurring in Alzheimer’s brain. While some imaging techniques are still under evaluation in the research setting, some have reached widespread clinical use. In this review, we provide an overview of the most commonly used imaging biomarkers in Alzheimer’s disease, from molecular PET imaging to structural MRI, emphasising the concept that multimodal imaging would likely prove to be the optimal tool in the future of Alzheimer’s research and clinical practice.


Author(s):  
James B. Brewer ◽  
Jorge Sepulcre ◽  
Keith A. Johnson

Advances in quantitative structural, functional, and molecular neuroimaging have provided new tools for objective, in vivo, assessment of critical aspects of Alzheimer’s disease and other neurodegenerative disorders. Measures of brain atrophy or brain dysfunction, coupled with measures of disease-linked pathology, might complement the history, physical and neurocognitive evaluation of patients and thereby improve predictive prognosis, especially at early stages of cognitive impairment where neurodegenerative etiology is less certain. Such imaging biomarkers are currently used in nearly all clinical trials of therapeutic agents for Alzheimer’s disease and are increasingly incorporated into clinical practice. In this chapter, imaging biomarkers are introduced and discussed to familiarize the reader with their potential research and clinical uses.


2014 ◽  
Vol 26 (5) ◽  
pp. 703-707 ◽  
Author(s):  
Antoine Leuzy ◽  
Eduardo Rigon Zimmer ◽  
Venkat Bhat ◽  
Pedro Rosa-Neto ◽  
Serge Gauthier

Since the original 1984 criteria for Alzheimer's disease (AD), put forth by a work group jointly established by the National Institute of Neurological and Communicative Disorders and Stroke (NINCDS) and the Alzheimer's Disease and Related Disorders Association (ADRDA) (McKhann et al., 1984), important advances have occurred in our ability to detect AD pathophysiology, with the incorporation of biomarkers – defined as anatomic, biochemical, or physiologic parameters that provide in vivo evidence of AD neuropathology (Cummings, 2011) – that can improve the certainty of AD diagnosis. Use of imaging biomarkers such as positron emission tomography (PET) with amyloid ligands, particularly in asymptomatic and pre-dementia stages of AD, however, has been the subject of debate (Dubois et al., 2013), with arguments both for and against the biomarker driven diagnosis of AD.


2010 ◽  
Vol 2010 ◽  
pp. 1-11 ◽  
Author(s):  
Benoît Delatour ◽  
Stéphane Epelbaum ◽  
Alexandra Petiet ◽  
Marc Dhenain

Identification of biomarkers of Alzheimer's Disease (AD) is a critical priority to efficiently diagnose the patients, to stage the progression of neurodegeneration in living subjects, and to assess the effects of disease-modifier treatments. This paper addresses the development and usefulness of preclinical neuroimaging biomarkers of AD. It is today possible to image in vivo the brain of small rodents at high resolution and to detect the occurrence of macroscopic/microscopic lesions in these species, as well as of functional alterations reminiscent of AD pathology. We will outline three different types of imaging biomarkers that can be used in AD mouse models: biomarkers with clear translational potential, biomarkers that can serve as in vivo readouts (in particular in the context of drug discovery) exclusively for preclinical research, and finally biomarkers that constitute new tools for fundamental research on AD physiopathogeny.


2019 ◽  
Author(s):  
Remika Mito ◽  
Thijs Dhollander ◽  
Ying Xia ◽  
David Raffelt ◽  
Olivier Salvado ◽  
...  

AbstractWhite matter hyperintensities (WMH) are commonly observed in elderly individuals, and are typically more prevalent in Alzheimer’s disease subjects than in healthy subjects. These lesions can be identified on fluid attenuated inversion recovery (FLAIR) MRI, on which they are hyperintense compared to their surroundings. These MRI-visible lesions appear homogeneously hyperintense despite known heterogeneity in their pathological underpinnings, and are commonly regarded as surrogate markers of small vessel disease in in vivo studies. Consequently, the extent to which these lesions contribute to Alzheimer’s disease remains unclear, likely due to the somewhat limited way in which these lesions are assessed in vivo. Diffusion MRI is sensitive to white matter microstructure, and might thus be used to investigate microstructural changes within WMH. In this study, we applied a method called single-shell 3-tissue constrained spherical deconvolution, which models white matter microstructure while also accounting for other tissue compartments, to investigate WMH in vivo. Diffusion MRI data and FLAIR images were obtained from Alzheimer’s disease (n = 48) and healthy elderly control (n = 94) subjects from the Australian Imaging, Biomarkers and Lifestyle study of ageing. WMH were automatically segmented and classified as periventricular or deep lesions from FLAIR images based on their continuity with the lateral ventricles, and the 3-tissue profile of different classes of WMH was characterised by three metrics, which together characterised the relative tissue profile in terms of the white matter-, grey matter-, and fluid-like characteristics of the diffusion signal. Our findings revealed that periventricular and deep lesion classes could be distinguished from one another, and from normal-appearing white matter based on their 3-tissue profile, with substantially higher free water content in periventricular lesions than deep. Given the higher lesion load of periventricular lesions in Alzheimer’s disease patients, the 3-tissue profile of these WMH could be interpreted as reflecting the more deleterious pathological underpinnings that are associated with disease. However, when alternatively classifying lesion sub-regions in terms of distance contours from the ventricles to account for potential heterogeneity within confluent lesions, we found that the highest fluid content was present in lesion areas most proximal to the ventricles, which were common to both Alzheimer’s disease subjects and healthy controls. We argue that whatever classification scheme is used when investigating WMH, failure to account for heterogeneity within lesions may result in classification-scheme dependent conclusions. Future studies of WMH in Alzheimer’s Disease would benefit from inclusion of microstructural information when characterising lesions.


2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Thanit Kunkeaw ◽  
Uthaiwan Suttisansanee ◽  
Dunyaporn Trachootham ◽  
Jirarat Karinchai ◽  
Boonrat Chantong ◽  
...  

AbstractAlzheimer’s disease (AD), one type of dementia, is a complex disease affecting people globally with limited drug treatment. Thus, natural products are currently of interest as promising candidates because of their cost-effectiveness and multi-target abilities. Diplazium esculentum (Retz.) Sw., an edible fern, inhibited acetylcholinesterase in vitro, inferring that it might be a promising candidate for AD treatment by supporting cholinergic neurons. However, evidence demonstrating anti-AD properties of this edible plant via inhibiting of neurotoxic peptides production, amyloid beta (Aβ), both in vitro and in vivo is lacking. Thus, the anti-AD properties of D. esculentum extract both in vitro and in Drosophila models of Aβ-mediated toxicity were elucidated. Findings showed that an ethanolic extract exhibited high phenolics and flavonoids, contributing to antioxidant and inhibitory activities against AD-related enzymes. Notably, the extract acted as a BACE-1 blocker and reduced amyloid beta 42 (Aβ42) peptides in Drosophila models, resulting in improved locomotor behaviors. Information gained from this study suggested that D. esculentum showed potential for AD amelioration and prevention. Further investigations in vertebrates or humans are required to determine the effective doses of D. esculentum against AD, particularly via amyloidogenic pathway.


Sign in / Sign up

Export Citation Format

Share Document